Dynavax Technologies Corporation DVAX shares are trading lower by $1.95 (8 percent) at $18.30 in Monday's session.
After last Thursday's close, the company announced it received FDA approval for Heplisav-B for the prevention of Hepatitis B in adults. It did manage a small gain in a volatile session on Friday, but finished well off its high for the of $22.25.
See Also: At Long Last, Dynavax Wins FDA Approval For Heplisav
Unfortunately for investors, Dynavax has been a "sell the news" scenario as the stock has nearly doubled since its July 27 low of $8.90 when it reached $24.45 on October 5.
In today's session, it was unable to clear Friday's close ($20.25), only reaching $20.20 and began to move lower. The ensuing decline took the stock beyond Friday's low ($18.60), reaching $18.20 as of 1:20 p.m. EST. That marks its lowest level since it bottomed on September 5 at $17.70.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.